Answers are grounded in this paper and cite their sources.
Sequential administration of romosozumab and zoledronate may increase osteonecrosis risk, highlighting clinical care needed.
Sequential administration of romosozumab followed by zoledronate may exacerbate the risk of MRONJ, underscoring the need for careful consideration in clinical applications.
No takes yet. Share an insight, caveat, or question.
Park et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: